Evidence map›Paper›PMID 33819023›Full record

ArticleBioconjugate chemistry2021

Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications.

Megan M Dacek, Darren R Veach, Sarah M Cheal, Lukas M Carter, Michael R McDevitt, Blesida Punzalan, Daniela Burnes Vargas, Thomas Z Kubik, Sebastien Monette, Brian H Santich and 7 more

Open access · greenAbstract read
In one paragraph

Article in Bioconjugate chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Establishment ofMolecular pharmaceutics · 2026
    Article
  2. Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13Rα2 CAR-T Cells In Vivo.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  3. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  4. Article
  5. Article
  6. Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a BivalentJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Megan M DacekMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Darren R VeachMolecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Sarah M ChealMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Lukas M CarterDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Michael R McDevittMolecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Blesida PunzalanMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Daniela Burnes VargasMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Thomas Z KubikMolecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Sebastien MonetteTri-Institutional Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and The Rockefeller University, New York, New York 10065, United States.
Brian H SantichDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Guangbin YangOrganic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Ouathek OuerfelliOrganic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Adam L KesnerDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Nai-Kong V CheungDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.ORCID 0000-0001-6323-5171
David A ScheinbergMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Steven M LarsonMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.ORCID 0000-0002-6111-7507
Simone KrebsMolecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.ORCID 0000-0002-9909-4531
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
T LYMPHOCYTE SUBSET FUNCTION POST-TRANSPLANTATIONP01CA023766 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PERALES, MIGUEL-ANGEL · 1985 to 2023
$59.0M
Translating Stress Response Targeted Therapy for B-Cell LymphomasP50CA192937 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DALLA-FAVERA, RICCARDO, ZELENETZ, ANDREW D. · 2016 to 2020
$10.9M
MSK Paul Calabresi Career Development Award for Clinical OncologyK12CA184746 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Omar Abdel-Wahab, Simon N. Powell · 2015 to 2026
$8.3M
Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.R35CA241894 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DAVID A SCHEINBERG · 2020 to 2026
$7.2M
RECOMBINANT ANTICD33 ANTIBODY FOR AMLR01CA055349 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SCHEINBERG, DAVID A · 1991 to 2020
$6.8M
DOTA-based pre-targeting of alpha emittersR01CA233896 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHEAL, SARAH MARIE · 2019 to 2023
$3.4M
Organic Synthesis at the Service of Biology and MedicineR50CA243895 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Ouathek Ouerfelli · 2019 to 2026
$1.9M
Development of a Novel Peptide Platform for Targeted PET Imaging and Radiotherapy of Breast CancerF32EB025050 · NIBIB · SLOAN-KETTERING INST CAN RESEARCH · PI CARTER, LUKAS MICHAEL · 2017 to 2019
$179k
Engineering CAR T cells to potentiate innate and adaptive immunityF31CA239511 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI DACEK, MEGAN · 2019 to 2021
$114k
NCATS NIH HHS UL1 TR002384NCI NIH HHS F31 CA239511NCI NIH HHS K12 CA184746NCI NIH HHS P01 CA023766NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA192937NCI NIH HHS R01 CA055349NCI NIH HHS R01 CA233896NCI NIH HHS R35 CA241894NCI NIH HHS R50 CA243895NIBIB NIH HHS F32 EB025050
6 · The paper itself

Abstract

Pretargeted imaging and radioimmunotherapy approaches are designed to have superior targeting properties over directly targeted antibodies but impose more complex pharmacology, which hinders efforts to optimize the ligands prior to human applications. Human embryonic kidney 293T cells expressing the humanized single-chain variable fragment (scFv) C825 (huC825) with high-affinity for DOTA-haptens (293T-huC825) in a transmembrane-anchored format eliminated the requirement to use other pretargeting reagents and provided a simplified, accelerated assay of radiohapten capture while offering normalized cell surface expression of the molecular target of interest. Using binding assays,

Indexed as

Cell EngineeringHaptensAnimalsAutoradiographyHEK293 CellsHumansMicePositron Emission Tomography Computed TomographyRadioimmunotherapyRadiopharmaceuticalsTissue DistributionXenograft Model Antitumor AssaysHaptensRadiopharmaceuticals

Identifiers

PMID33819023
PMCPMC8284561
OpenAlexW3146209029

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.